Here's what the patents actually claim: not a better version of the standard eye drug, but a molecule that blocks a second target entirely. The question worth answering is why a company would bother.
Standard anti-VEGF drugs block VEGF, the protein that tells blood vessels in the eye to grow and leak. They work — but in some patients the disease pushes back. One reason is PDGF, a second signal that helps the abnormal vessels mature and wrap themselves in supporting cells, making them harder to kill.
So the bet is: block VEGF and PDGF together. Kodiak Sciences' grant US11155610B2 covers dual PDGF/VEGF antagonists — a single agent aimed at both. The companion publication US20200262905A1 stakes out the same dual-target ground a year earlier.
Think of it like fighting a weed. Cutting the stem (VEGF) slows it, but if the roots (PDGF's stabilizing effect) are intact, it grows back. Hit both and the regrowth is harder. That's the biological logic the patent encodes.
The crosswalk worth keeping: a 'dual antagonist' isn't marketing — it's a specific, claimed mechanism with two named targets, and the patent is where you verify the claim. When a company says its eye drug is differentiated, the patent tells you whether the difference is a real second target or just a tweak.
Whether the dual approach wins in patients is a clinical question the patent can't settle. But the crosswalk from 'why two signals?' to a specific granted claim shows how a scientific hypothesis becomes a defensible commercial bet — one target at a time.